Form 4: GoodRx CFO McGinnis Granted 443,852 RSUs

GoodRx Holdings, Inc. Chief Financial Officer Christopher A McGinnis was granted 443,852 restricted stock units, vesting quarterly over three years.

Summary

• Christopher A McGinnis, Chief Financial Officer & Treasurer of GoodRx Holdings, Inc., was granted 443,852 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A common stock.
• The RSUs will vest ratably in 12 equal quarterly installments.
• The first vesting is scheduled for April 15, 2026, and is subject to continued service through each applicable vesting date.
• Following this transaction, Mr. McGinnis beneficially owns 126,321 shares of Class A Common Stock directly and 443,852 derivative Restricted Stock Units directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to its role in executive retention and alignment of interests, though it is a routine compensation event.

Positives

• The grant of Restricted Stock Units aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing sustained company performance.
• The multi-year vesting schedule acts as a retention mechanism for a key executive.

Negatives

• The future conversion of RSUs into common stock will result in a minor dilutive effect on existing shareholders.

Future Outlook

The Restricted Stock Units are scheduled to vest in 12 equal quarterly installments, with the first vesting on April 15, 2026, contingent upon Christopher A McGinnis's continued service to the company through each applicable vesting date.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units to key executives is a standard practice in the technology and healthcare sectors. This form of equity compensation is widely used to attract, retain, and motivate senior management by aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• StockSavvy.ai notes that the multi-year, quarterly vesting schedule for executive equity grants is a common industry standard, similar to compensation structures observed at comparable companies in the digital health space such as Teladoc Health (TDOC) or Hims & Hers Health (HIMS).
• The grant size for a Chief Financial Officer at a company of GoodRx's market capitalization is generally within expected ranges for executive compensation packages designed for retention and performance incentives.

Related Party Transactions

• Grant of 443,852 Restricted Stock Units to Christopher A McGinnis, the Chief Financial Officer & Treasurer, as part of his executive compensation package.

Stakeholder Impact

• Shareholders: Potential minor future dilution upon vesting of RSUs, but also benefit from increased executive alignment with long-term company performance.
• Employees (CFO): Receives a significant long-term equity incentive, fostering retention and motivation.

Next Steps

• The Restricted Stock Units will begin vesting on April 15, 2026, and continue in quarterly installments over the subsequent three years, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation grant and does not introduce new material information that would fundamentally alter the investment thesis for GoodRx Holdings, Inc. While positive for executive retention and alignment, it is not expected to significantly impact the stock price or warrant a change in investment strategy based solely on this filing.

Keywords

GoodRx, GDRX, Form 4, Restricted Stock Unit, RSU, Executive Compensation, Stock Grant, CFO